October 2016

CMS’ Oncology Care Model program is bringing bundled payments to cancer care. With drug costs so high and hard to control, the 195 participating practices will have to figure out other ways to control costs if they want to beat financial benchmarks and earn bonuses.
Thomas Reinke
Current versions by ASCO, NCCN, and others may not be right for insurers, but they are eyeing new ways to crunch the numbers for cost and outcomes.
Ed Silverman
Experts are rethinking the routine cancer screen. In the future, screening recommendations may be tailored, risk-stratified, and based on our genes.
Charlotte Huff
Patients and doctors are fighting the urge to rush in and treat cancer right away. Insurers must walk a fine line.
Richard Mark Kirkner
The intrepid young oncologist’s criticism of cancer screening and surrogate endpoints has stirred up controversy. He says he just wants drugmakers, others to meet high standards of evidence.
Interview by Peter Wehrwein
Success in the Medicare Stars ratings system requires a culture that looks beyond short-term success to ensure long-term survival.
Vanessa Pawlak

Legislation & Regulation: Campaign 2016
The fate of the health care reform law will be determined by the outcome of a joyless election.
Richard Mark Kirkner
Costs Cast Shadow on Optimism About Treatment
Peter Wehrwein
Tomorrow’s Medicine
Carbon fiber is more flexible than metal, so it may help fractured bones heal faster. Carbon fiber hardware may also have an application in oncology.
Thomas Morrow, MD
He has other serious health problems and needs a clinician to quarterback the care for all his conditions—not just the cancer.
Zachary Hafner